Education
About Us
Working with TipRanks
Follow Us
Corteva (CTVA)
NYSE:CTVA
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.17Last Year’s EPS
1.13Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive outlook driven by strong 2025 results (14% EBITDA growth, margin expansion to >22%, $2.9B FCF), successful strategic progress (Bayer settlement accelerating licensing and reducing royalty risk), and reiterated 2026 guidance with continued productivity targets. Key near-term risks include Q4 timing-related volume softness, competitive pricing pressures in Crop Protection (notably Brazil), currency headwinds in 2025 and expected tariff impacts in 2026, along with higher SG&A/R&D and potential normalization of working capital that could temper free cash flow. On balance, the company highlighted more material progress and upside catalysts than offsets, with a clear path to additional licensing revenue and margin/cash improvement.Company Guidance
Strong Full-Year Financial Performance
Full-year 2025 operating EBITDA of $3.85 billion, up roughly $470 million (about +14% year-over-year), with operating EBITDA margin expanding over ~215 basis points to above 22%.
Revenue and Organic Sales Growth
Full-year organic sales grew ~4% versus prior year; second-half sales up 4% with operating EBITDA up 16% in H2 driven by better price/mix in Seed and volume gains across both segments.
Record Free Cash Flow and Capital Returns
Free cash flow improved by about $1.2 billion to $2.9 billion in 2025; returned approximately $1.5 billion to shareholders in fiscal 2025 via dividends and share repurchases and targeting ~$500 million of share repurchases in 1H 2026.
Seed Business Momentum and Cost/Royalty Improvements
Seed delivered organic growth in every region, share gains in corn and soy, ~$340 million of net cost improvements and ~$90 million of royalty improvement in 2025; net royalty expense ended the year around $120 million.
Crop Protection Growth and Innovation Pipeline
Crop Protection delivered top-line and bottom-line growth in 2025, volume up ~5% for the year, biologicals produced double-digit volume gains, and the business has a $9 billion pipeline of differentiated technologies; CP delivered over $300 million of productivity/cost benefits for the full year.
Bayer Agreement Accelerates Licensing and Reduces Royalty Risk
Comprehensive resolution with Bayer completed, ~$610 million payment mostly completed; expect royalty neutrality in 2026 (2 years ahead of prior plan), acceleration of corn licensing to as early as 2027 (accelerated ~5 years), earlier introduction of third-gen platforms (~2 years earlier) and entry into U.S. cotton licensing; agreement expected to generate ~ $1 billion aggregate earnings upside over the next 10 years.
2026 Guidance Reiterated with Growth
2026 operating EBITDA guidance range $4.0–$4.2 billion with midpoint $4.1 billion (~+7% vs. 2025 midpoint); operating EPS guide $3.45–$3.70 (about +7% at midpoint); ~ $120 million improvement in net royalty expense, ~$200 million productivity savings, and a currency tailwind expected to add ~ $75 million to EBITDA.
Separation Progress and Capital Structure Planning
Separation remains on track for second half (likely Q4) 2026 with plans for Form 10 filings, management team announcements, Board appointments and IT separation; estimated net dissynergies roughly $100 million with ~$50 million built into 2026 guide.
CTVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 03, 2026 | $75.04 | $75.12 | +0.11% |
Nov 04, 2025 | $62.33 | $63.50 | +1.88% |
Aug 06, 2025 | $70.81 | $70.69 | -0.17% |
May 07, 2025 | $62.01 | $66.36 | +7.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Corteva (CTVA) report earnings?
Corteva (CTVA) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Corteva (CTVA) earnings time?
Corteva (CTVA) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTVA EPS forecast?
CTVA EPS forecast for the fiscal quarter 2026 (Q1) is 1.17.